Stock Market & Financial Investment News

News Breaks October 22, 2012 07:46 EDT ARIA ARIAD price target raised to $30 from $25 at Stifel Nicolaus After surveying 35 hematology/oncology specialists, Stifel Nicolaus believes the survey suggests that ARIAD's ponatinib in front-line CML has significant potential. The firm thinks the company's outlook for sales of the drug is conservative and it maintains a Buy rating. News For ARIA From The Last 14 Days Check below for free stories on ARIA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 08:22 EDT ARIA ARIAD shares should be bought on weakness, says BMO Capital Subscribe for More Information May 16, 2013 07:29 EDT ARIA Leerink to host a bus tour Boston Biopharma Bus Tour travels throughout Boston on May 16-17. May 7, 2013 12:02 EDT ARIA ARIAD management to meet with JMP Securities Subscribe for More Information 07:39 EDT ARIA ARIAD reports Q1 EPS (36c), consensus (38c) Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.